Guidelines for the management of iron deficiency anaemia

A F Goddard, A S McIntyre, B B Scott, for the British Society of Gastroenterology

Summary
Iron deficiency anaemia in men and post-menopausal women is most commonly caused by gastrointestinal blood loss or malabsorption. Examination of both the upper and lower gastrointestinal tract is therefore an important part of the investigation of patients with such anaemia. In the absence of overt blood loss or any obvious cause, all patients should have upper gastrointestinal endoscopy, including small bowel biopsy, and colonoscopy or barium enema to exclude gastrointestinal malignancy. Further gastrointestinal investigation is only warranted in transfusion dependent anaemia or where there is visible blood loss. Treatment of an underlying cause will cure the anaemia but even when no cause is detected the long term outlook is good.

1.0 Introduction
Iron deficiency anaemia (IDA) occurs in 2–5% of adult men and post-menopausal women in the developed world and is a common cause of referral to a gastroenterology clinic (4–13% of referrals). While menstrual blood loss is the commonest cause of IDA in pre-menopausal women, blood loss from the gastrointestinal (GI) tract is the commonest cause in adult men and post-menopausal women. Asymptomatic colonic and gastric carcinoma may present with IDA and exclusion of these conditions is of prime concern. Malabsorption (most frequently from coeliac disease), poor dietary intake, previous gastrectomy, and NSAID use are not unusual but there are many other possible causes (table 1). The management of IDA is often suboptimal with most patients being incompletely investigated if at all.

These guidelines are primarily for gastroenterologists and GI surgeons but would be applicable to other doctors seeing patients with IDA.

The investigation of overt blood loss is not considered in these guidelines.

2.0 Definitions

2.1 Anaemia
The diagnostic criteria for anaemia in IDA vary (Hb 10–11.5 g/dl for women and <12.5–13.8 g/dl for men) between studies. The lower limit of the normal range of haemoglobin concentration for the laboratory performing the test should therefore probably be used to define anaemia*. It is not known at what level of haemoglobin investigations should be initiated. However, there is no a priori reason why mild anaemia should be less indicative of important disease than severe anaemia.

Table 1. Gastrointestinal (GI) diseases presenting with iron deficiency

<table>
<thead>
<tr>
<th>Occult GI blood loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common</td>
</tr>
<tr>
<td>NSAID use</td>
</tr>
<tr>
<td>Colonic cancer/polyp</td>
</tr>
<tr>
<td>Gastric cancer</td>
</tr>
<tr>
<td>Angiodysplasia</td>
</tr>
<tr>
<td>Crohn's disease</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
</tr>
<tr>
<td>Uncommon</td>
</tr>
<tr>
<td>Oesophagitis†</td>
</tr>
<tr>
<td>Peptic ulcer†</td>
</tr>
<tr>
<td>Oesophageal cancer</td>
</tr>
<tr>
<td>Water melon stomach</td>
</tr>
<tr>
<td>Intestinal telangiectasia</td>
</tr>
<tr>
<td>Lymphoma, leiomyoma and other small bowel tumours</td>
</tr>
<tr>
<td>Duodenal polyph (Brunner's gland adenoma)</td>
</tr>
<tr>
<td>Carcinoma of the ampulla of Vater</td>
</tr>
<tr>
<td>Meckel's diverticulum</td>
</tr>
<tr>
<td>Hookworm</td>
</tr>
<tr>
<td>Malabsorption</td>
</tr>
<tr>
<td>Coeliac disease</td>
</tr>
<tr>
<td>Gastrectomy (partial and total) and gastric atrophy</td>
</tr>
<tr>
<td>Gut resection or bypass</td>
</tr>
<tr>
<td>Bacterial overgrowth</td>
</tr>
<tr>
<td>Whipple's disease</td>
</tr>
<tr>
<td>Lymphangiectasia</td>
</tr>
</tbody>
</table>

Although common causes of acute bleeding they are uncommon causes of occult bleeding.

2.2 Iron Deficiency (ID)
Microcytosis (mean corpuscular volume (MCV) lower than the normal range) is characteristic of ID but it may also occur in much less common conditions such as thalassaemia (when the red cell count is usually elevated). Haemoglobinopathies frequently cause microcytosis in certain ethnic groups but this should not be presumed to be the cause unless confirmed by laboratory testing. Microcytosis may be absent in combined deficiency (e.g. with folate deficiency) which may be recognised by a raised red cell distribution width (RDW). The anaemia of chronic disease due to the inability to use iron may also present with microcytosis.

Serum ferritin concentration is the most powerful test for ID***. A serum ferritin concentration of <12 µg/dl is diagnostic of ID**. However, serum ferritin may be raised above 12–15 µg/dl in patients with ID and concurrent chronic inflammation, malignancy, or hepatic disease, although if the concentration is >100 µg/dl, ID is almost certainly not present.

A further test is usually only required in patients when doubt still exists as to the presence of iron deficiency*** and advice from a haematologist should be sought. Red cell protoporphyrin concentration and

Abbreviations used in this paper: ID, iron deficiency; IDA, iron deficiency anaemia; RDW, red cell distribution width; GI, gastrointestinal; MCV, mean corpuscular volume.
transferrin saturation of $<$30% may help the
diagnosis but a therapeutic response to three
weeks of oral iron or a bone marrow aspiration
are the only ways of confirming true
deficiency***.10 New tests which involve meas-
uring the serum transferrin binding receptor/
ferritin ratio show promise in distinguishing
between anaemia of chronic disease and iron
deficiency but are not yet widely available.

The need for investigation of patients with
iron deficiency but no anaemia has not been
assessed in clinical studies.

3.0 Investigations

3.1 HISTORY

A careful dietary history is important to
identify iron deficient diets. However, since
borderline deficient diets are common in
patients, a positive dietary history should not
be presumed as the cause of anaemia and a full
GI investigation is still required. The presence
of upper and lower GI symptoms should be
documented although these rarely correlate
with investigation findings. The use of aspirin
and analgesics, particularly NSAIDs, should be
noted and stopped whenever possible. The use
of these drugs and anticoagulants should not
usually deter investigation. Family history of
haematological disorders (for example thalass-
emia and sideroblastic anaemia), telangiecta-
sia, and bleeding disorders should be sought.

3.2 EXAMINATION

Careful examination, although seldom con-
tributory, may reveal a relevant abdominal
mass or cutaneous signs of gastrointestinal
blood loss (for example Peutz-Jeghers and
Osler-Weber-Rendu syndromes).

3.3 GASTROINTESTINAL EVALUATION

GI investigations should be considered in all
patients in whom IDA has been confirmed
unless there is a history of significant non-GI
blood loss. In the absence of suggestive
symptoms the order of investigations will be
determined by local availability. It is usually
convenient to do upper GI endoscopy first
although in the elderly investigation of the
colon is likely to be more productive. Upper GI
endoscopy can be expected to reveal a cause in
between 30 and 50% of patients.5-8 Small bowel
biopsies should be taken during this endoscopy
as 2–3% of patients presenting with IDA have
celiac disease***.3-6 If the patient is unable to
have upper GI endoscopy, a barium meal
should be performed in addition to blood
antidysonmial antibody.

- Small bowel biopsies should be taken
deroendoscopy as 2–3% of patients
presenting with iron deficiency anaemia
have celiac disease***.

- Serum ferritin concentration is the most
powerful test for iron deficiency***.

Unless the upper GI endoscopy reveals
carcinoma or coeliac disease, all patients
should then undergo examination of the lower
GI tract*** as dual pathology (lesions in
both the colon and upper GI tracts) occurs in
around 10–15% of patients. In particular,
oesophagitis, erosions, aphthous ulceration,
and peptic ulcer should not at this stage be
accepted as the cause of the iron deficiency.
Colonoscopy (possibly at the same session
as the upper GI endoscopy—'bidirectional
endoscopy') has the advantage that it will dem-
strate angiodysplasia and allow biopsy of any
lesion. However, double contrast barium
enema is a sufficient alternative,23-25 with or
without sigmoidoscopy*,11 especially if the
facilities for colonoscopy are limited or the
success rate of complete colonoscopy is poor
within a particular unit. Omission of sig-
moidoscopy appears safe if digital rectal ex-
amination is negative in the absence of a changed
bowel habit or rectal bleeding.13

3.4 FURTHER EVALUATION

Further direct visualisation of the small bowel
is probably not necessary unless the IDA is
transfusion dependent or there has been visible
blood loss**.3-7 Follow-up studies have shown
this approach to be safe.5-9 provided dietary
deficiency is corrected and/or NSAIDs stopped
and the haemoglobin concentration moni-
tored. However, if IDA is transfusion depend-
ent, enteroscopy may be helpful to detect and
treat small bowel angiodysplasia***.16-17 Small
bowel radiology is rarely of use unless the
history is suggestive of Crohn's disease**.9-18
Mesenteric angiography is of limited use but
may be valuable in transfusion dependent IDA
for demonstrating vascular malformations.
Similarly, diagnostic laparotomy with on-table
endoscopy may be considered in cases which
have defied other investigation but is unlikely to
be resorted to unless there is transfusion
dependent anaemia*.8,9 Meckel's diverticulum
usually presents with visible blood loss
(melaena) but may rarely present with IDA and
should be considered in young adults. Diagnos-
tic laparotomy is the most sensitive test for
Meckel’s diverticulum while perentericane
scans have very poor sensitivity**.9-19

Other investigations, including routine as-
sessments of the liver and renal function, and
clotting studies are of no diagnostic value
unless the history is suggestive of systemic
disease**.1 Faecal occult blood testing is of no
benefit in the investigation of IDA, being
insensitive and non-specific**.4,20 Very occa-
sionally, urinary tract tumours may present
with IDA and therefore the presence of haema-
turia should be excluded.

4.0 Management

4.1 AIM OF TREATMENT

The aim of treatment should be to restore
haemoglobin levels and MCV to normal and
replentish body stores. If this cannot be
achieved, consideration should be given to fur-
ter evaluation.
4.2 IRON THERAPY
Treatment of an underlying cause should prevent further iron loss but all patients should have iron supplementation both to correct anaemia and replenish body stores**. This is achieved most simply and cheaply with ferrous sulphate 200 mg three times daily although ferrous gluconate and ferrous fumarate are as effective. A liquid preparation may be tolerated when tablets are not. Ascorbic acid enhances iron absorption** and should be considered when response is poor. Parenteral iron should only be used when there is intolerance to at least two oral preparations or non-compliance. Parenteral iron treatment is painful (when given intramuscularly), expensive, and may cause anaphylactic reactions. The rise in haemoglobin is no quicker than with oral preparations. The haemoglobin concentration should rise by 2 g/dl after 3–4 weeks. Failure to do so is usually due to poor compliance, misdiagnosis, continued blood loss, or malabsorption. Iron supplementation should be continued for three months after correction of anaemia to replenish iron stores*.

- All patients should receive iron supplementation to correct anaemia and replenish body stores**.

4.3 FOLLOW UP
Once normal, the haemoglobin concentration and red cell indices should be monitored at intervals. We suggest three monthly for one year and then after a further year. Additional oral iron should be given if the haemoglobin or MCV falls below normal (a ferritin estimation should also be done in doubtful cases). Further investigation is only necessary if the haemoglobin and MCV cannot be maintained in this way. It is reassuring to know that iron deficiency does not return in most patients in whom a cause for IDA is not found after upper GI endoscopy, small bowel biopsy and barium enema.13

4.4 SUMMARY FLOW CHART
A management flow chart is shown in fig 1.

5.0 Special considerations
5.1 CO-MORBIDITY
The appropriateness of investigating patients with severe co-morbidity or other reason (in some circumstances advanced age) especially if the result would not influence management, should be carefully considered and discussed with patients and carers when possible.

5.2 PRE-MENOPAUSAL WOMEN
Menstruating women present a large healthy population in which IDA is common, occurring in 5–10%23 24 Menstrual loss, especially menorrhagia, pregnancy, and breast feeding are usually responsible.24 History is unreliable in quantifying menstrual loss,25 although pictorial blood loss assessment charts have been shown to have a sensitivity and specificity of around 80% for detecting menorrhagia.26 There are little data on the yield of GI investigation in menstruating women with IDA27 28 but significant GI pathology has been detected in these studies.

- Iron deficiency anaemia occurs in 5–10% of menstruating women.

Because of the increasing incidence of important pathology with age, we recommend that those more than 45 years are investigated according to the above guidelines. In the absence of data in those less than 45 years, we recommend that only patients with upper GI symptoms have endoscopy and small bowel biopsy. The remainder should have antienzymysial antibody determinations (and IgA measurement to exclude IgA deficiency which makes the test unreliable) to exclude coeliac disease. Colonic investigation in patients less than 45 years should only be done if there are...
Goddard, McIntyre, Scott

colonic symptoms, a strong family history of colorectal carcinoma (for example two first degree relatives or one first degree relative <45 years), or persistent IDA following iron supplementation and correction of potential causes of losses (for example menorrhagia, blood donation, poor diet).

5.3 YOUNG MEN

Although the incidence of important GI pathology in young men is low, there are no data on the yield of investigation in those with IDA. In the absence of such data we recommend that investigation of young men should occur according to the guidelines.

5.4 POST-GASTRECTOMY

IDA is to be expected after gastrectomy, both partial and total, due to poor chelation and IDA is to be expected after gastrectomy, both partial and total, due to poor chelation and absorption of iron as a result of the loss of ascorbic acid and hydrochloric acid, and loss of free iron in exfoliated cells. It would seem reasonable, therefore, only to investigate those whose IDA persists on iron supplementation or who present with IDA many years after partial gastrectomy.

6.0 Suggested targets for audit

We suggest that:
- 90% of patients (other than menstruating women) with iron deficiency anaemia and no obvious cause should have both an upper GI endoscopy with small bowel biopsy and either colonoscopy or barium enema (unless a firm cause is found with the first investigation).
- Resolution of anaemia should be achieved by six months in 80% of patients.
- 90% of those not responding to treatment should have been considered for further investigation.

7.0 Suggested topics for further research

- The need to investigate iron deficiency without anaemia.
- The importance of stratifying for risk of significant disease according to haemoglobin level.
- The long term prognosis of colonic neoplasms discovered by investigating iron deficiency anaemia compared with those found in other ways.
- The role of investigation in young men and menstruating women.
- The value of CT colonography in the investigation of IDA.

8.0 Strength of recommendations made in these guidelines

The strength of evidence for recommendations given in these guidelines is indicated by *, **, or *** in the text as follows:
- *Based on meta-analysis or large randomised trials.
- **Based on good evidence from trials, but less convincing (e.g. smaller numbers).
- ***Based on specialist opinion.

9.0 Formulation of guidelines

These guidelines were drawn up by the following process:

1. Medline search using the term “iron deficiency anaemia”.
2. Review of abstracts of all references.
3. Review of all papers felt to be relevant to guidelines.
4. Review of references not cited by Medline felt to be relevant to guidelines.
5. Drafts of guidelines formulated by authors.
6. Initial guidelines reviewed by BSG Clinical Services and Standards Committee.
7. Guidelines amended by authors.
8. Steps (6) and (7) repeated twice.
9. Guidelines accepted by BSG Clinical Services and Standards Committee.
10. Guidelines reviewed by BSG council.
11. Guidelines amended by authors.
12. Guidelines accepted by council and submitted for publication.

10.0 Date for review

April 2004.

11.0 References

Guidelines for the management of iron deficiency anaemia

Guidelines for the management of iron deficiency anaemia

A F Goddard, A S McIntyre and B B Scott

Gut 2000 46: iv1-iv5
doi: 10.1136/gut.46.suppl_4.iv1

Updated information and services can be found at:
http://gut.bmj.com/content/46/suppl_4/iv1

These include:

References
This article cites 26 articles, 9 of which you can access for free at:
http://gut.bmj.com/content/46/suppl_4/iv1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Errata
An erratum has been published regarding this article. Please see next page or:
http://gut.bmj.com/content/47/6/871.2.full.pdf

Topic Collections
Articles on similar topics can be found in the following collections

- Colon cancer (1547)
- Pancreatic cancer (660)
- Coeliac disease (537)
- Endoscopy (1003)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
LETTERS TO THE EDITOR

Inflammation at the neo squamo-columnar junction in Barrett's oesophagus

EDITOR,—In the recent article entitled “Inflammation at the gastro-oesophageal junction (carditis) in patients with symptomatic gastro-oesophageal reflux disease: a prospective study” (Gut 1999;48:484–488), the authors determined that mucosal injury at the gastric cardia is highly localised to the region adjacent to the squamo-columnar junction in patients with gastro-oesophageal reflux disease (GORD). This is of particular interest to us in view of our recent work on the inflammatory response in Barrett’s oesophagus. We have shown that while the Barrett’s segment may be relatively devoid of inflammation, the neo squamo-columnar junction continues to excite an inflammatory reaction. These results were independent of patient medication (n=50, p<0.05), similar to the study by Lembo et al.

Lembo et al suggest that carditis may be due to “wear and tear” at the gastro-oesophageal junction as well as secondary to gastro-oesophageal reflux and Helicobacter pylori infection. Our similar findings in patients with Barrett’s oesophagus suggest that the gastric and intestinal types of epithelium (either in normal stomach or in metaplastic oesophagus) may represent an adaptation to frequent exposure to refluxate. In contrast, the squamo-columnar junction is particularly susceptible to inflammation. It is interesting to speculate whether it is the proximal squamous oesophagus or the distal reflux area which excites the inflammatory response at the junction of these epithelia. In the study by Lembo et al, the biopsies containing squamous mucosa alone were not particularly inflamed; this suggests that it may be the interaction of cytokines generated from both the columnar and squamous epithelium in close proximity which are necessary to generate an inflammatory reaction. This may have implications for the strictures which occur in proximal Barrett’s oesophagus.

R C FITZGERALD
Digestive Diseases Research Centre, St Bart’s and the Royal London School of Medicine and Dentistry, Turner Street, London E1 2AD, UK r.c.fitzgerald@mds.qmw.ac.uk


Mother to child transmission of anti-S cerevisiae mannan antibodies (ASCA) in non-IBD families

EDITOR,—We enjoyed the recent study by Sutton and colleagues (Gut 2000;46:58–63) which confirmed our previous findings that elevated anti-S cerevisiae mannan antibodies (ASCA), are a familial trait in Crohn’s disease. The lack of concordance in marital

R C FITZGERALD
Digestive Diseases Research Centre, St Bart’s and the Royal London School of Medicine and Dentistry, Turner Street, London E1 2AD, UK

Table 1 Distribution of anti-S cerevisiae mannan antibodies (ASCA) in 94 diabetic families

<table>
<thead>
<tr>
<th>Family</th>
<th>Parent</th>
<th>Child</th>
<th>Total number of ASCA+</th>
<th>ASCA+ born of ASCA+ parents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children</td>
<td>Father</td>
<td>ASCA+</td>
<td>22 0 0 0 0</td>
<td>22 0 0 0 0</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td></td>
<td>44 5 1</td>
<td>60 0 0 0 0</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td></td>
<td>60 3 1</td>
<td>64 0 0 0 0</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td></td>
<td>36 6 0 0</td>
<td>12 0 0 0 0</td>
</tr>
<tr>
<td>4</td>
<td>5</td>
<td></td>
<td>36 6 1 0</td>
<td>11 0 0 0 0</td>
</tr>
<tr>
<td>5</td>
<td>6</td>
<td></td>
<td>0 0 0</td>
<td>0 0 0 0 0</td>
</tr>
<tr>
<td>6</td>
<td>7</td>
<td></td>
<td>2 4 1 0</td>
<td>14 3 0 0 0</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>188 15 6 9</td>
<td>225 8 8 0 0</td>
</tr>
</tbody>
</table>

Figure 1 Pedigrees of the 14 diabetic families with at least one ASCA positive subject. +, presence of ASCA; shaded box, patient with diabetes.

4 Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibody bodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease (IBD) families. A total of 413 serum samples were collected from 94 diabetic families (table 1). One patient per family had type I diabetes. ASCA were detected by ELISA as previously described. Distribution of ASCA is given in fig 1 and table 1. Twenty three subjects (5.6%) were ASCA positive: six had diabetes and 14 were healthy. ASCA positive subjects were distributed within only 14 of 96 families. Seven of these families only one subject (parent) was positive for ASCA. The remaining 16 ASCA positive subjects clustered within seven families. All ASCA positive children were born of an ASCA positive mother. These results show that familiality of ASCA occurs independently of Crohn’s disease and suggest vertical transmission of the marker from mother to child. Whether this is related to the observed higher risk of Crohn’s disease transmission from mother to child than from father to child is unknown. Further work is needed to assess if the presence of ASCA may predict an increased risk of Crohn’s disease in offspring.

D POULAIN
B SENDID
F PAJARDY
PM DANZE
JF COLOMBEL
Laboratoire de Mycologie Fondamentale et Appliquée, Equipe INSERM 99-15,
Laboratoire de Recherche sur les Maladies Inflammatoires Intestinales (CRI 4U004B), Unité fonctionnelle de génotypage HLA, CH et U Lille, 59037, France

Correspondence to: J F Colombel, jfcolombel@chru-lille.fr

www.gutjnl.com
observed a strong correlation for both the mother-child and father-child pairs. This differs from Poulain and colleagues who only evaluated clinically unaffected families from Crohn’s disease (CD) probands. We also note that our analysis used statistical methods for quantitative data (antibody levels) which enhances statistical assessment, particularly when limited by small data sets. Poulain’s analysis compares qualitative data (seropositive or seronegative), and the small number of relevant pairs may be insufficient to support their conclusion statistically. We agree with them on the need to assess the possibility that ASCA may predict increased risk for CD in unaffected individuals.

Table 1 Correlation coefficients for IgG anti-S cretivase mannann antibodies (ASCA) among 33 first degree relatives without evidence of Crohn’s disease

<table>
<thead>
<tr>
<th>Type of pairs</th>
<th>IgG ASCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mother-daughter</td>
<td>0.135</td>
</tr>
<tr>
<td>Father-daughter</td>
<td>0.423</td>
</tr>
<tr>
<td>Father-son</td>
<td>0.404</td>
</tr>
</tbody>
</table>

Sir Francis Avery Jones British Society of Gastroenterology Research Award 2001

Applications are invited by the Committee of the British Society of Gastroenterology who will recommend to the Council the recipient of the 2001 Award. Applications (TEN COPIES) should include:

- A manuscript (2 A4 pages ONLY) describing the work conducted
- A bibliography of relevant personal publications
- An outline of the proposed content of the lecture, including title
- A written statement confirming that all or a substantial part of the work has been personally conducted in the UK or Eire.

An applicant need not be a member of the Society. The recipient will be required to deliver a 20 minute lecture at the Annual meeting of the Society in Glasgow in March 2001. Applications (TEN COPIES) should be made to the Endoscopy Section Secretary, British Society of Gastroenterology, 3 St Andrews Place, London NW1 4LB by 1 December 2000.

British Society of Gastroenterology Hopkins Endoscopy Prize 2001

Applications are invited by the Endoscopy Committee of the British Society of Gastroenterology who will recommend to the Council the recipient of the 2001 Award. Applications (TEN COPIES) should include:

- A manuscript (2 A4 pages ONLY) describing the work conducted
- A bibliography of relevant personal publications
- An outline of the proposed content of the lecture, including title
- A written statement confirming that all or a substantial part of the work has been personally conducted in the UK or Eire.

An applicant need not be a member of the Society. The recipient will be required to deliver a 20 minute lecture at the Annual meeting of the Society in Glasgow in March 2001. Applications (TEN COPIES) should be made to the Endoscopy Section Secretary, British Society of Gastroenterology, 3 St Andrews Place, London NW1 4LB by 1 December 2000.

American College of Gastroenterology 2001 International GI Training Grants Programme

The ACG International GI Training (IGT) Grant Programme provides funding for clinical or clinical research training in gastroenterology and hepatology so that an individual can acquire or develop new cognitive knowledge or a technical skill. This newly acquired knowledge or skill would then be used to improve patient care in the applicant’s geographic area. Physicians outside of the United States and Canada are eligible to apply. At least one fellowship with a maximum of $10 000 per IGT fellowship will be awarded during 2001, for a training period of not less than six months. Awards will be made by a special committee of the ACG and will be based upon the applicant’s credentials, the merit of the proposed training by the selected host training centre and the potential for enhancing the field of gastroenterology in the applicant’s home country. Application forms can be obtained from the ACG administrative office, 4900B South 31st Street, Arlington, Virginia 22206-1656. Tel: +1 703 820 7400; fax: +1 703 931 4520; website: www.acg-gi.org. Deadline for submission of application is 1 April 2001.

3rd European Federation of Autonomic Societies (EFAS)

The third European Federation of Autonomic Societies (EFAS) meeting in conjunction with the annual meeting of the sections “Autonomic nervous system” of the German Neurological Society, “Diabetes and Nervous System” of the German Neurological Society, and “Autonomic Nervous System” at the University of Erlangen-Nuremberg, Germany, will be held in Erlangen, Germany on 26–28 April 2001. Abstract deadline: 20 December 2000. Further information: Professor Dr M J Hilz, Department of Neurology, University of Erlangen-Nuremberg, Schwabachanlage 6, D-91054 Erlangen, Germany; Tel: +49 9131 8534444; fax: +49 9131 8534328; website: www.gutjnl.com
www.neurologie.med.uni-erlangen.de/oeffentliche_Veranstaltungen.htm

Cleveland Clinic Florida's Gastroenterology Update 2001

Cleveland Clinic Florida will be sponsoring a postgraduate course entitled “Gastroenterology Update 2001” to be held on 10–11 February 2001 in Fort Lauderdale, Florida, USA. Further information: Sally Jagelman, Manager of Continuing Medical Education, Cleveland Clinic Florida, 3000 West Cypress Creek Road, Fort Lauderdale, FL 33309, USA. Tel: +1 954 978 5539; fax: +1 954 978 5056; email: jagemls@ccf.org

GI malignancies can be prevented and treated: from the bench to the bedside

This international meeting will be held on 14–17 February 2001 in Jerusalem and the Dead Sea, Israel. Further information: Mari-lyne Katz, Secretariat, GI Malignancies, Target Tours, PO Box 29041, Tel Aviv 61290, Israel. Tel: +972 3 5175150; fax: +972 3 5175155; email: gi@targetconf.com

Redefining Priorities in Gastroenterology

This congress will be held on 11–14 April 2001 in Monte Carlo, Italy. It will be chaired by Professor Massimo Crespi (Rome, Italy) and Professor Eammon Quigley (Cork, Ireland). Further information: Maddalena Massaro, Project Leader, AISC-AIM Group, Via A Ristori 38, 00187 Rome, Italy. Tel: +39 06 809681; fax: +39 06 80968229; email: m.massaro@aisc.it.

Gastroenterology and Endotherapy: XIXth European Workshop

This course, to introduce the experienced gastroenterologist to the growing field of therapeutic endoscopy, will be held on 18–20 June 2001 in Brussels, Belgium. Further information: Mrs Nancy Beauprez, Gastroenterology Department, Erasme Hospital, Route de Lennik 808, B-1070 Brussels. Tel: +32 02 555 49 00; fax: +32 02 555 49 01; email: beauprez@ulb.ac.be

CORRECTION

The authors of Guidelines for the management of iron deficiency anaemia (Gut 2000;46(suppl IV)) would like to correct an error they made. In section 2.2, second paragraph, the wrong unit was used for ferritin. Instead of µg/dl, it should have been µg/l (or ng/ml). The authors apologise for any confusion this may have caused.